NCT01529840

Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome

Norditropin Treatment in Subjects With Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in Europe. The aim of this trial is to evaluate the effect of somatropin (Norditropin®) on final height in children with Noonan syndrome having being treated for up to 10 years with somatropin (Norditropin®) for the attainment of an optimal final height in the original trial S/GHD/004/NOO.

Conditions

• Genetic Disorder
• Noonan Syndrome

Interventions

Type	Name	Description
DRUG	somatropin	Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
DRUG	somatropin	Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit

Timeline

• Start date: 1990-06-01
• Primary completion: 2005-09-01
• Completion: 2005-09-01
• First posted: 2012-02-09
• Last updated: 2017-01-18

Locations

1 site across 1 country: Sweden